Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dow Jones Industrial Average ETF (DIA) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Dow Jones Industrial Average ETFTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Dow Jones Industrial Average ETF vs Inovio Pharmaceuticals Inc — how do they compare? Dow Jones Industrial Average ETF trades at $537.24, while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Dow Jones Industrial Average ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

DIAINO
52-Week High
$542.79$2.87
52-Week Low
$444.64$0.66
Market Cap
$78.55M
Sector
Health
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dow Jones Industrial Average ETF

DIA (SPDR Dow Jones Industrial Average ETF) trades at $537.13, down 0.35% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF's dividend schedule includes upcoming payments of $1.41 and $0.28 per share through mid-2026. Recent market coverage highlights the Dow's milestone above 53,000 points, driven by financials and tech exposure, while broader ETF flows show strong investor interest in core index heavyweights amid defensive positioning.

Outlook remains positive given the Dow's blue-chip composition and recent market momentum, though risks include tech volatility and geopolitical tensions. The ETF offers stable dividend income and exposure to large-cap value stocks, but investors should monitor macroeconomic indicators and Fed policy for potential headwinds.

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dow Jones Industrial Average ETF

The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on DIA

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO